CTRI/2023/08/056451尚未招募2 期
Efficacy & safety of a standardized extract from Bacopa monnieri in children and adolescents with attention deficit hyperactivity disorder (ADHD): A randomized, double blind, placebo-controlled with an extended open label study.
atural Remedies Pvt. Lt0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Children adolescents of both sexes between 6 and 16 years old (both inclusive), who exhibit mild to moderate ADHD, with predominantly inattentive or combined presentation, according to DSM V criteria (assessed via the MINI KID).
- •2.Inattentive subset and hyperactivity subset of not greater than 22 on SNAP IV scale.
- •3.Voluntary Assent to participate in the study from all those who are more than 7 years of age.
- •4.Informed Consent Form signed by legal guardians.
- •5.Results of laboratory tests (chemistry, blood count and urine), physical examination and vital parameters with no clinically significant changes (clinically significant changes are defined as laboratory results requiring acute drug intervention, indicating severe illness, or requiring further medical evaluation according to the discretion of the investigator)
排除标准
- •1.Wechsler Intelligence Scale for Children Fourth Edition Short Form (WISC IVSF score) subjects whose scores are less than 80.
- •To be administered by a psychiatrist or a clinical psychologist.
- •2.With the history of diagnosis with previous cognitive development delay.
- •3.Research participants with known hypersensitivity to the other medications. History of alcohol or drug abuse by the research participant.
- •4.Where the immediate concern is around another Primary psychiatric diagnoses other than ADHD.
- •5.Diagnosis of psychiatric comorbidities, except for simple phobia, adjustment disorders, learning disorders, oppositional defiant disorder, sleep disorders, mild anxiety and or mild depressions.
- •6.History of seizures (except for mild febrile seizures) within 2 years from the time of recruitment.
- •7.Diagnosis of Tourette Syndrome and chronic tics
- •8.Research participants who are making use of drugs for the treatment of ADHD in the last three months.
- •9.Research participants who are making use of anticonvulsants, antidepressants, and antipsychotics up to 6 weeks prior to study entry or during the same.
- •10.History of past or present pregnancy as confirmed by the participant who have attained menarche.
- •11.Patients at identified risk of suicide through clinical interview.
- •12.Children or adolescents with ADHD predominantly hyperactive or impulsive
- •13.Other conditions considered by the investigator as reasonable for disqualification of the subjectâ??s participation in the study. (To be administered by a clinical psychologist)
研究者
相似试验
招募中
1 期
Clinical evaluation of the efficacy of purified bioactive peptides from Spirulina Platensis algae on the healing of wounds after periodontal flap surgery (double-blinded randomized clinical trial)IRCT20221021056257N1Tabriz University of Medical Sciences30
招募中
4 期
The study to evaluate the efficacy and safety of Bipolar Radiofrequency-Assisted Lipolysis for Facial ContouringHealthy patientBipolar Radiofrequency-Assisted Lipolysis, Facial ContouringTCTR20230516008ASTRACO MEDICAL NETWORKS LTD.39
招募中
4 期
The study to evaluate the efficacy and safety of Bipolar Radiofrequency-Assisted Lipolysis for cheek and nasolabial fold ContouringHealthy patientBipolar Radiofrequency-Assisted Lipolysis, Cheek and nasolabial fold ContouringTCTR20230515001ASTRACO MEDICAL NETWORKS LTD.39
招募中
4 期
The study to evaluate the efficacy and safety of Bipolar Radiofrequency-Assisted Lipolysis combined with Adjustable-depth fractional microneedle bipolar radiofrequency for periorbital RejuvenatioHealthy PatientBipolar Radiofrequency-Assisted Lipolysis,Adjustable-depth fractional microneedle bipolar radiofrequency,periorbital RejuvenationTCTR20230417001ASTRACO MEDICAL NETWORKS LTD.38
已完成
2 期
Randomized, Open Label Study of the Safety and Efficacy of BIO-11006 in the Treatment of Advanced Nonâ??Small Cell Lung Cancer.CTRI/2018/01/011152Biomarck Pharmaceuticals60